Early findings from an ongoing study report that a group of 20 firefighters tested after the Palisades and Eaton fires had ...

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

A leading global democracy research institute says democratic “backsliding” must be turned around quickly—warning that after ...

Full-year results and business updateClinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized ...

The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death ...

MeiraGTx's innovative gene therapies for ocular diseases & more are backed by strong clinical data and funding. Click here to find out why MGTX stock is a Buy.

To participate in the call, please dial 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll) and ask for the IMUNON Phase 3 protocol call. A live webcast of the call will also ...

Introduction to Blockchain Security Blockchain technology has revolutionized the way we transact and store data, offering ...

Why not all African countries should venture into vaccine business ANALYSIS | The African Union has embarked on one of its ...

Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect ...